Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Total Current Liabilities of $728.0 million for Q1 2026, down 32.33% year-over-year from $1.1 billion in Q1 2025, and down 17.42% quarter-over-quarter from $881.6 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $728.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 32.33% year-over-year to $728.0 million; the TTM figure through Mar 2026 stood at $728.0 million (down 32.33% YoY), while the FY2025 annual figure was $881.6 million, down 21.96% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $728.0 million, down from $881.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $1.1 billion in Q4 2024, with the low at $602.0 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $846.6 million (2023), against an average of $887.2 million.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities soared 47.59% in 2022, then plunged 32.33% in 2026.
- Amneal Pharmaceuticals' Total Current Liabilities stood at $752.8 million in 2022, then advanced by 12.46% to $846.6 million in 2023, then soared by 33.45% to $1.1 billion in 2024, then retreated by 21.96% to $881.6 million in 2025, then dropped by 17.42% to $728.0 million in 2026.
- Business Quant data shows AMRX's Total Current Liabilities at $728.0 million in Q1 2026, $881.6 million in Q4 2025, and $862.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.57 Bn | 334.51 Mn | 883.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 883.19 Mn |
| Mar 31, 2026 | 728.05 Mn |
| Dec 31, 2025 | 881.63 Mn |
| Sep 30, 2025 | 862.11 Mn |
| Jun 30, 2025 | 1.11 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.10 Bn |
| Jun 30, 2024 | 1.11 Bn |
| Mar 31, 2024 | 834.39 Mn |
| Dec 31, 2023 | 846.60 Mn |
| Sep 30, 2023 | 760.60 Mn |
| Jun 30, 2023 | 777.35 Mn |
| Mar 31, 2023 | 703.71 Mn |
| Dec 31, 2022 | 752.80 Mn |
| Sep 30, 2022 | 818.00 Mn |
| Jun 30, 2022 | 993.06 Mn |
| Mar 31, 2022 | 602.04 Mn |
| Dec 31, 2021 | 677.24 Mn |
| Sep 30, 2021 | 667.34 Mn |